Results

Total Results: 2,078 records

Showing results for "drugs".

461. Hepatitis-C Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_executive.pdf
     November 01, 2012 - and telaprevir (trade name Incivek®), for treatment of chronic HCV genotype 1 infection.24,25 Both drugs … Packets on unpublished and published trials were solicited from manufacturers of included antiviral drugs … their effects would be helpful for guiding health care providers’ treatment choices between these drugs … Third, few trials have evaluated the regimens approved specifically by the FDA for these drugs, limiting … are currently in active development, and further studies with new drugs and drug regimens are expected

462. Title (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/mental-illness-adults-prisons_research-protocol.pdf
     September 13, 2012 - lower risk for developing movement disorders and other unpleasant side effects, but some of these drugs … in most prison formularies for treating bipolar disorder and schizoaffective disorder because these drugs … Drug therapy/ Exp antidepressive agents/ Psychotropic drugs/ Therapeutic use.fs. … OR exp neuroleptic agent/ OR exp neuroleptic drugs/ OR psychopharmacotherapy/ OR psychotropic agent … / OR psychotropic drugs/ 8 Pharmacologic interventions Text words (drug ADJ (based OR counseling

463. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Available: http://www.cesar.umd.edu/cesar/drugs/ketamine. pdf. 4. … CNS Drugs. 2012 Mar 1;26(3):189-204. … PMID: 23200737 http://www.cesar.umd.edu/cesar/drugs/ketamine.pdf http://www.cesar.umd.edu/cesar/drugs … Rochester (MI): JHP Pharmaceuticals, LLC; 2011 Jun. 4 p.

464. Slide 1 (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/marketing_evidence_evans.ppt
     September 13, 2006 - evidence” to healthcare consumers: Applying social marketing to evidence about the harms and benefits of pharmaceuticals … Agency for Healthcare Research and Quality Conference: Communicating Harms and Benefits of Prescription Drugs … information to counter the effects of marketing by companies with competing interests (e.g., tobacco, pharmaceuticals … and health science dissemination & translation fields Case Study 4: Risk Communication About Pharmaceuticals … promotion tool Evidence-based AED Dissemination Model Potential Lessons for Health Care Pharmaceuticals

465. Appendix-F2-Surveillance-Report-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/appendix-f2-surveillance-report-1.xlsx
     November 22, 2021 - Title Appendix F2 - Data Abstraction of Harms Outcomes TCA_PCT WAE WAE SAE SAE Cardiac Rhythm Abnormalities Cardiac Rhythm Abnormalities Cardiac Rhythm Abnormalities Cardiac Rhythm Abnormalities Cognitive Effects Cognitive Effects Cognitive Effects Cognitive Effects Dry Mouth Dry Mout…

466. Appropriate Use of Pharmacologic Therapies for Osteoporosis Fracture Prevention | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/osteoporosis-fracture-prevention
     April 12, 2018 - Appropriate Use of Pharmacologic Therapies for Osteoporosis Fracture Prevention Timeline August 15, 2017 Topic Initiated April 12, 2018 Research Protocol Long-Term Drug Therapy and Drug Holidays for Osteoporotic Fracture Prevention April 23, 2019 …

467. Community Pharmacy/Call Center Assessment of Medication Effectiveness & Safety | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/medicine-safety-call-center/research
     December 02, 2009 - Community Pharmacy/Call Center Assessment of Medication Effectiveness & Safety Research Report December 2, 2009 Download Main Document PDF 442.6 KB This report is available in PDF (443 kB) only. People using assistive technology may not be able to fully access information in this file. For assistance,…

468. App-F2-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
     September 20, 2022 - TCA_PCT Table F-2a. Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time (Wk) Time Category WAE: n WAE: N SAE: n SAE: N Cardiac Rhythm Abnormalities: Specific AE Cardiac Rhythm Abnormalities: n Cardiac Rhythm Abnormalities: N N Randomized Cognitive Eff…

469. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Results The table below lists the four topics for which (1) preliminary phase III data for drugs or

470. EHC Protocol: Addressing Social Isolation To Improve Health of Older Adults: A Rapid Evidence Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs4-computerized-cds-protocol.pdf
     May 08, 2023 - EHC Protocol: Addressing Social Isolation To Improve Health of Older Adults: A Rapid Evidence Review 1 Evidence-based Practice Center Rapid Review Protocol Project Title: Making Healthcare Safer IV: Computerized Clinical Decision Support to Prevent Medication Errors and Adverse Drug Events Review …

471. Treatment of Hepatitis C Virus Infection in Adults: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c-treatment-future_research.pdf
     April 01, 2013 - • How does the efficacy of antiviral drugs change with lower treatment adherence? … Pharmaceuticals. … and “How does the efficacy of antiviral drugs change with lower treatment adherence?” Table 5. … How does efficacy of antiviral drugs change with lower treatment adherence? … Pharmaceuticals.

472. For persons who present with acute cough illness (ACI), what is the comparative effectiveness of various interventions for reducing inappropriate antimicrobial use? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-persons-who-present-with-acute-cough-illness-aci-what-is-the-comparative-effectiveness-of-various-interventions-for-reducing-inappropriate-antimicrobial-use
     April 12, 2012 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

473. S23 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s23.pdf
     October 01, 2007 - Relative Risk, Number Needed to Harm, Frequency Information, and Public Health Impact for Selected Drugs … Drug Discovery, Development, and Translation Work- shop 2: Understanding the Benefits and Risks of Pharmaceuticals … Yale Study Parks FDA Review of Cold Drugs. The Yale Herald News Online 2000. … Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia:

474. App-F2-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
     September 20, 2022 - TCA_PCT Table F-2a. Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time (Wk) Time Category WAE: n WAE: N SAE: n SAE: N Cardiac Rhythm Abnormalities: Specific AE Cardiac Rhythm Abnormalities: n Cardiac Rhythm Abnormalities: N N Randomized Cognitive Eff…

475. S77 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s77.pdf
     October 01, 2007 - number of prescriptions filled for 30-day periods, we are unable to calculate the actual use of generic drugs … a sliding-scale basis for this group, and because copayments are tied to the cost of their specific drugs

476. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - The modalities can be used alone or in combination, at variable doses (of drugs) or regimens (of mechanical … history of abnormal surgical bleeding or bleeding disorder, prior medications (e.g., antiplatelet drugs … Studies evaluated the following thromboprophylaxis classes (and combinations thereof): antiplatelet drugs … Among four RCTs of low versus high dose FXaI, studies favored higher dose FXaI (multiple drugs, mostly … In particular, there are sparse RCTs or NRCSs that evaluated antiplatelet drugs (e.g., aspirin), VKA

477. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - The modalities can be used alone or in combination, at variable doses (of drugs) or regimens (of mechanical … history of abnormal surgical bleeding or bleeding disorder, prior medications (e.g., antiplatelet drugs … Studies evaluated the following thromboprophylaxis classes (and combinations thereof): antiplatelet drugs … Among four RCTs of low versus high dose FXaI, studies favored higher dose FXaI (multiple drugs, mostly … In particular, there are sparse RCTs or NRCSs that evaluated antiplatelet drugs (e.g., aspirin), VKA

478. Medication-Therapy-Management Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medication-therapy-management_executive.pdf
     November 01, 2014 - require multiple chronic conditions or a minimum number or level of expenditures on prescription drugs … following 3 elements: – Comprehensive medication review covering all prescription and nonprescription drugs … Proximal and intermediate outcomes included number of drugs, identification of drug therapy problems … Drugs. 2009;69(4):393-406. Epub: 2009/03/28. PMID: 19323584. 10. 108th U.S. Congress.

479. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/arthritis-psoriatric_research-protocol.pdf
     December 06, 2010 - Available therapies for PsA include corticosteroids, oral disease-modifying antirheumatic drugs (DMARDs … Finally, very little is known about the benefits or risks of these drugs in different patient subgroups … Simponi® Tocililizumab Actemra®, RoActemrai® • Comparators: All key questions: all review drugs

480. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/psoriasis-chronic_research-protocol.pdf
     January 10, 2012 - approaches to psoriasis treatment. 4,5,11 Biologic therapies for psoriasis use genetically engineered drugs … (Schwarz Pharma Manufacturing; OSI Pharmaceuticals Inc.) … Teva Pharmaceuticals USA (Barr Pharmaceuticals) Symptomatic control of severe, recalcitrant, … oral capsule) GlaxoSmithKline (CatalentPharmaSo lutions;Accucaps Industries, Ltd.; Banner Pharmaceuticals … to UVA radiation, followed by exposure to UVA radiation ranging from 320–400 nm • 8-MOP® (ICN Pharmaceuticals